Search results
Results from the WOW.Com Content Network
Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). [ 4 ] [ 5 ] The medication improves sexual desire, increases the number of satisfying sexual events, and decreases the distress associated with low sexual desire. [ 6 ]
Bremelanotide, sold under the brand name Vyleesi, is a medication used to treat low sexual desire in women. [2] Specifically it is used for low sexual desire which occurs before menopause and is not due to medical problems, psychiatric problems, or problems within the relationship.
Flibanserin [1] and Bremelanotide [3] were developed for raising sexual desire in women, whereas similar conditions in men are treated using medications for sexual dysfunction. [4] On the other hand, down-regulation on libido comes in two approaches: a direct or an indirect mechanism.
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
The World Health Organization (WHO) published the WHO Surgical Safety Checklist in 2008 in order to increase the safety of patients undergoing surgery. [1] The checklist serves to remind the surgical team of important items to be performed before and after the surgical procedure in order to reduce adverse events such as surgical site infections or retained instruments. [1]
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Flibanserin. PubMed provides review articles from the past five years (limit to free review articles)
Preventive care and screenings for women. [28] "[A]ll Food and Drug Administration approved contraceptive methods, sterilization procedures, and patient education and counseling for all women with reproductive capacity". [29] This mandate applies to all employers and educational institutions except for religious organizations.
A study in The BMJ, with over 1.6 million women, found that users of vaginal rings with ethinylestradiol and etonogestrel have a 6.5 times increased risk of venous thrombosis compared to non-users. [ 19 ] [ 20 ] Epidemiological studies have shown that oral contraceptives that contain desogestrel can increase the risk of blood clots (venous ...